Cartesian Therapeutics (RNAC) Change in Accured Expenses (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Change in Accured Expenses of -$850000.0 for Q1 2026, up 60.97% year-over-year from -$528037.6 in Q1 2025, and down 180.26% quarter-over-quarter from $1.1 million in Q4 2025.
Cartesian Therapeutics (RNAC) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Change in Accured Expenses data on file, last reported at -$850000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$850000.0, up 60.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 million (up 9.35% YoY), and the FY2025 annual result was -$3.6 million, up 46.77% from the prior year.
- Change in Accured Expenses declined to -$850000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.2 million in Q2 2022 and troughed at -$6.4 million in Q1 2024.
- A 5-year average of -$689882.4 and a median of -$432000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 716.67% in 2023, then plunged 222.78% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $1.6 million in 2022, then tumbled by 171.21% to -$1.1 million in 2023, then surged by 203.56% to $1.2 million in 2024, then decreased by 8.94% to $1.1 million in 2025, then plunged by 180.26% to -$850000.0 in 2026.
- Business Quant data shows RNAC's Change in Accured Expenses at -$850000.0 in Q1 2026, $1.1 million in Q4 2025, and -$432000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -850,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -850,000.00 |
| Mar 31, 2026 | -850,000.00 |
| Dec 31, 2025 | 1.06 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | -432,000.00 |
| Sep 30, 2025 | -432,000.00 |
| Jun 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 592,000.00 |
| Sep 30, 2024 | 592,000.00 |
| Jun 30, 2024 | -2.07 Mn |
| Jun 30, 2024 | -2.07 Mn |
| Mar 31, 2024 | -6.43 Mn |
| Mar 31, 2024 | -6.43 Mn |
| Dec 31, 2023 | -1.12 Mn |
| Dec 31, 2023 | -1.12 Mn |